It is evident with so many people focused on COVID-19 that biotech stocks with coronavirus vaccines and treatments have gained a lot of attention.
The Pfizer and BioNTech vaccine is developed on mRNA science, more straightforward, quicker, and cheaper to produce than standard vaccines. Even so, amid the enormous capital and expertise of Pfizer, the large pharmaceutical firm has failed to reach the production goals it initially set for the vaccine, needing to cut the original 100 million doses in 2020 to 50 million last month.
The development issues are not restricted to vaccines for Covid-19 either. The FDA authorized the use of antibody drugs to treat Covid-19 last month, for example, complicated to develop. Other indications include diagnostics and cell therapies are in development. Flowing are the key performers from the Biotech sectors in yesterday’s market session.
Xenetic Biosciences Inc. (NASDAQ:XBIO) shares were trading up 193.52% at $3.17 at the time of writing on Wednesday following declaration that it saw positive data from its partner PJSC Pharmsynthez about its pivotal Phase 3 clinical study leveraging PolyXen to develop a treatment for anemia in patients with chronic kidney disease (CKD).
Xenetic Biosciences Inc. (NASDAQ:XBIO) share price went from a low point around $0.44 to briefly over $1.85 in past 52 weeks, though shares have since pulled back to $3.17. XBIO market cap has remained high, hitting $20.45M at the time of writing, giving it price-to-sales ratio of more than 60.
If we look at the recent analyst rating XBIO, Maxim Group initiated coverage on XBIO shares with a Buy rating.
Moderna Inc. (MRNA) last closed at $156.59, in a 52-week range of $17.68 to $178.50. The healthcare firm recently declared that the Swiss Federal Government has increased its confirmed order commitment from 4.5 million to 7.5 million doses of Moderna’s vaccine candidate against COVID-19, mRNA-1273. Analysts have a consensus price target of $122.60.
GeoVax Labs Inc. (GOVX) stock soar by 79.06% to $5.73. The company on November 30, 2020 reported license agreement with NIH to support continued advancements in vaccine development. The most recent rating by Maxim Group, on November 19, 2020, is at a Buy.
Intec Pharma Ltd (NASDAQ:NTEC) Shares headed rising, higher as much as 34.10% after declaring that it has entered into a feasibility agreement with GW Research Limited, London, U.K. to explore using the Accordion Pill (AP) platform for an undisclosed research program.. The most recent rating by Ladenburg Thalmann, on December 09, 2020, is at a Buy.
Atossa Therapeutics Inc. (NASDAQ:ATOS) fall -39.03% after losing more than -$0.56 on Wednesday after the company reported pricing of $20.0 million underwritten public offering.
Sorrento Therapeutics Inc. (SRNE) last closed at $8.21, in a 52-week range of $1.55 to $19.39. The company reported that it received US FDA clearance to proceed with Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in healthy volunteers and in newly diagnosed COVID-19 Patients.
Greenwich LifeSciences Inc. (GLSI) stock soar by 998.35% to $57.10 after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
Jaguar Health Inc. (NASDAQ:JAGX) Shares headed falling, lower as much as -11.45%. The most recent rating by Rodman & Renshaw, on July 11, 2017, is at a Buy.
Lipocine Inc. (NASDAQ:LPCN) fall -21.43% after losing more than -$0.36 on Wednesday following the announcement from the company that the U.S. Food and Drug Administration has granted tentative approval to TLANDO
Tonix Pharmaceuticals Holding Corp. (TNXP) last closed at $0.64, in a 52-week range of $0.39 to $2.46. On December 3, 2020, the firm declared positive phase 3 RELIEF study results for TNX-102 SL 5.6 mg in Fibromyalgia.
SELLAS Life Sciences Group Inc. (SLS) stock soar by 73.17% to $6.39. The company on December 7, 2020 revealed an exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China. The most recent rating by Oppenheimer, on November 01, 2018, is at an Outperform.
AIkido Pharma Inc. (NASDAQ:AIKI) Shares headed rising, higher as much as 4.07% after declaring the publication of positive results from its Artificial Intelligence/Machine Learning Sponsored Research Program in the field of Pancreatic Cancer.
Celsion Corporation (NASDAQ:CLSN) rose 12.90% after gaining more than $0.08 on Wednesday.
ADMA Biologics Inc. (ADMA) last closed at $2.22, in a 52-week range of $1.45 to $4.65. The firm recently announced $100 million credit facility loan amendment with perceptive advisors.
Onconova Therapeutics Inc. (ONTX) stock soar by 1.75% to $0.32. On November 23, 2020, the company reported the filing of an investigational new drug application for Multi-kinase CDK4/6 Inhibitor ON 123300. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.